The role of ovarian ablation in the adjuvant therapy of breast cancer

Current Oncology Reports

Volumn 10, Issue 1, 2008, Pages 27-37

  Tan, Sing Huang ^b   Wolff, Antonio C ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; BUSERELIN; CALCIUM; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTRADIOL; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GONADORELIN AGONIST; GOSERELIN; IBANDRONIC ACID; LETROZOLE; LEUPRORELIN; METHOTREXATE; PREDNISOLONE; RISEDRONIC ACID; TAMOXIFEN; TAXANE DERIVATIVE; TRIPTORELIN; VITAMIN D; ZOLEDRONIC ACID;

ADJUVANT THERAPY; AMENORRHEA; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENDOMETRIOSIS; FERTILIZATION IN VITRO; HOT FLUSH; HUMAN; LIFESTYLE MODIFICATION; MASTECTOMY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARIECTOMY; OVARY CANCER; OVARY FUNCTION; OVERALL SURVIVAL; OVULATION INHIBITION; PRECOCIOUS PUBERTY; PREMENOPAUSE; PROGNOSIS; PROSTATE CANCER; REVIEW; RISK REDUCTION; SECONDARY OSTEOPOROSIS; UTERUS MYOMA;

AMENORRHEA; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; OVARIECTOMY; OVARY; RADIOTHERAPY; TAMOXIFEN;

EID: 38149063362     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0006-y     Document Type: Review

References (74)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Hankey BF, Miller B, Curtis R, Kosary C: Trends in breast cancer in younger women in contrast to older women. J Natl Cancer Inst Monogr 1994, 7-14.
3. Theriault RL, Sellin RV: Estrogen-replacement therapy in younger women with breast cancer. J Natl Cancer Inst Monogr 1994, 149-152.
4. Pujol P, Daures JP, Thezenas S, et al.: Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer 1998, 83:698-705.
5. Aebi S, Gelber S, Castiglione-Gertsch M, et al.: Is chemotherapy alone adequate for young women with oestrogen-receptor-positivc breast cancer? Lancet 2000, 355:1869-1874.
6. Beatson G: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896, 2:104-107.
7. Paterson R, Russell MH: Clinical trials in malignant disease. II. Breast cancer: value of irradiation of the ovaries. J Fac Radiol 1959, 10:130-133.
8. Dowsett M: Estrogen receptor: methodology matters. J Clin Oncol 2006, 24:5626-5628.
9. Lees AW, Giuffre C, Burns PE, et al.: Oophorectomy versus radiation ablation of ovarian function in patients with metastatic carcinoma of the breast. Surg Gynecol Obstet 1980, 151:721-724.
10. Lee YT: Therapeutic castration for advanced breast cancer. Am J Surg 1971, 122:42-49.
11. Davidson NE: Ovarian ablation as treatment for young women with breast cancer. J Natl Cancer Inst Monogr 1994, 95-99.
12. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Lancet 1993, 341:1293-1298.
13. Roche H, Mihura J, de Lafontan B, et al.: Castration and tamoxifen vs chemotherapy (FAC) for premenopausal, node and receptors positive breast cancer patients: a randomized trial with a 7 years follow-up [abstract 132. Proc Am Soc Clin Oncol 1996, 15:117.
14. Love RR, Duc NB, Allred DC, et al.: Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 2002, 20:2559-2566.
15. Love RR, Dinh NV, Quy TT, et al.: Survival with adjuvant surgical oophorectomy and tamoxifen in premenopausal women with operable breast cancer [abstract 552]. Proc Am Soc Clin Oncol 2007, 25:552.
16. Love RR, Duc NB, Havighurst TC, et al.: Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 2003, 21:453-457.
17. Love RR, Duc NB, Dinh NV, et al.: Mastectorny and oophorectomy by menstrual cycle phase in women with operable breast cancer. J Natl Cancer Inst 2002, 94:662-669.
18. Hughes LL, Gray RJ, Solin LJ, et al.: Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study. Cancer 2004, 101:969-972.
19. Leung SF, Tsao SY, Teo PM, et al.: Ovarian ablation failures by radiation: a comparison of two dose schedules. Br J Radiol 1991, 64:537-538.
20. Meakin JW, Allt WE, Beale FA, et al.: Ovarian irradiation and prednisone therapy following surgery and radiotherapy for carcinoma of the breast. Can Med Assoc J 1979, 120:1221-1229.
21. Ejlertsen B, Mouridsen HT, Jensen MB, et al.: Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol 2006, 24:4956-4962.
22. Groenvold M, Fayers PM, Petersen MA, Mouridsen HT: Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial. Breast Cancer Res Treat 2006, 98:275-284.
23. Adjuvant Breast Cancer Trials Collaborative Group: Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl Cancer Inst 2007, 99:516-525.
24. Karten MJ, Rivier JE: Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev 1986, 7:44-66.
25. Porter RN, Smith W, Craft IL, et al.: Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet 1984, 2:1284-1285.
26. Skarin G, Nillius SJ, Wibell L, Wide L: Chronic pulsatile low dose GnRH therapy for induction of testosterone production and spermatogenesis in a man with secondary hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1982, 55:723-726.
27. Huirne JA, Lambalk CB: Gonadotropin-releasing-hormone-receptor antagonists. Lancet 2001, 358:1793-1803.
28. Rossmanith WG, Wirth U, Sasse V, Lauritzen C: Treatment with different GnRH analogues in women: preliminary evidence for disparant effects on serum androgen concentrations. Horm Metab Res 1991, 23:198-199.
29. Parinaud J, Oustry P, Perineau M, et al.: Randomized trial of three luteinizing hormone-releasing hormone analogues used for ovarian stimulation in an in vitro fertilization program. Fertil Steril 1992, 57:1265-1268.
30. Lindner CH, Braendle W, Bettendorf G: Endocrine profiles during GnRH-agonist therapy using different application forms. Proceedings of the 13th World Congress of Gynecology and Obstetrics, Singapore; 1991:1491.
31. Filicori M, Flamigni C, Cognigni G, et al.: Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women. J Clin Endocrinol Metab 1993, 77:130-133.
32. Dowsett M, Mehta A, Mansi J, Smith IE: A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients. Br J Cancer 1990, 62:834-837.
33. Schmid P, Untch M, Kosse V, et al.: Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol 2007, 25:2509-2515.
34. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992, 339:71-85.
35. Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1996, 348:1189-1196.
36. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998, 352:930-942.
37. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
38. Carlini P, Bria E, Cuppone F, et al.: Adjuvant LH-RH agonists for premenopausal early breast cancer: a meta-analysis of randomized clinical trials (RCTs) exploring the magnitude of the disease-free and overall survival (DFS/OS) benefit [ASCO abstract 592]. J Clin Oncol 2007, 25:abstract 592.
39. Cuzick J, Ambroisine L, Davidson N, et al.: Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007, 369:1711-1723.
40. Jonat W, Kaufmann M, Sauerbrei W, et al.: Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002, 20:4628-4635.
41. von Minckwitz G, Graf E, Geberth M, et al.: CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93). Eur J Cancer 2006, 42:1780-1788.
42. Castiglione-Gertsch M, O'Neill A, Price KN, et al.: Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003, 95:1833-1846.
43. Rutqvist L: Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: a randomised trial by the Cancer Research Campaign (CRC) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Cancer Group and the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (G.I.V.I.O) [ASCO abstract 251]. Proc Am Soc Clin Oncol 1999, 18:abstract 251.
44. Soreide JA, Varhaug JE, Fjosne HE, et al.: Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study. Eur J Surg Oncol 2002, 28:505-510.
45. Robert NJ, Wang M, Cella D, et al.: Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary node-negative receptor-positive breast cancer ≤ 3 cm [ASCO abstract 16]. Proc Am Soc Clin Oncol 2003, 22:abstract 16.
46. Boccardo F, Rubagorti A, Amoroso D, et al.: Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000, 18:2718-2727.
47. Jakesz R, Hausmaninger H, Kubista E, et al.: Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer: Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002, 20:4621-4627.
48. Roche H, Kerbrat P, Bonneterre J, et al.: Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. Ann Oncol 2006, 17:1221-1227.
49. De Matteis A, Montedoro D, Nuzzo F, et al.: Hormonotherapy with goserelin depot after adjuvant chemotherapy in premenopausal women with early breast cancer: is there any benefit? Eur J Cancer 1998, 34(Suppl):44-44(1).
50. Kaufmann M, Graf E, Jonat W, et al.: Goserelin versus control after adjuvant, risk-adapted chemotherapy in pre-menopausal patients with breast cancer. GABG trial IV-B-93 [ASCO abstract 588]. J Clin Oncol 2004, 22:abstract 588.
51. Arriagada R, Le MG, Spielmann M, et al.: Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol 2005, 16:389-396.
52. Davidson NE, O'Neill AM, Vukov AM, et al.: Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (ES188). J Clin Oncol 2005, 23:5973-5982.
53. De Placido S, De Laurentiis M, De Lena M, et al.: A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. Br J Cancer 2005, 92:467-474.
54. Baum M, Hackshaw A, Houghton J, et al.: Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Cancer 2006, 42:895-904.
55. International Breast Cancer Study Group: Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93. Breast 2001, 10(Suppl:130-138.
56. Bernhard J, Zahrieh D, Castiglione-Gertsch M, et al.: Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients - the International Breast Cancer Study Group Trial VIII. J Clin Oncol 2007, 25:263-270.
57. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998, 351:1451-1467.
58. PERCHE trial (IBCSG 26-02): Premenopausal Endocrine Responsive Chemotherapy trial. http://www.ibcsg.org. Accessed October 2007.
59. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al.: Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007, 25:820-828.
60. Rossi E, Esposito G, Di Rella F, et al.: Endocrine effects of letrozole + triptorelin compared to tamoxifen + triptorelin as adjuvant treatment of premenopausal patients with early breast cancer. The NCI Naples Breast Cancer Group [ASCO abstract 578]. J Clin Oncol 2007, 25:abstract 578.
61. BOOG1-The Promise Study (PRemenopausal Optimal Management IS Endocrine therapy): an international, multicentre, open label, randomised phase III study to compare immediate optimal endocrine adjuvant therapy versus standard chemotherapy followed by the same endocrine therapy in pre- or perimenopausal patients with early hormone receptor-positive breast cancer. http://www.arimidex.net. Accessed October 2007.
62. Petrek JA, Naughton MJ, Case LD, et al.: Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006, 24:1045-1051.
63. Pagani O, O'Neill A, Castiglione M, et al.: Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998, 34:632-640.
64. Hillner BE, Ingle JN, Chlebowski RT, et al.: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042-4057.
65. Jaschke A, Bastert G, Solomayer EF, et al.: Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow - a longtime follow-up [ASCO abstract 529]. J Clin Oncol 2004, 22:abstract 529.
66. Powles T, McCloskey E, Kurkilahti M: Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebo-controlled multicenter trial [ASCO abstract 528]. J Clin Oncol 2004, 22:abstract 528.
67. Saarto T, Vehmanen L, Blomqvist C, Elomaa I: Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients [ASCO abstract 527]. J Clin Oncol 2004, 22:abstract 527.
68. Delmas PD, Balena R, Confravreux E, et al.: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997, 15:955-962.
69. Berry DA, Cirrincione C, Henderson IC, et al.: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006, 295:1658-1667.
70. SOFT (IBCSG 24-02): Suppression of Ovarian Function Trial. http://www.ibcsg.org. Accessed October 2007.
71. TEXT (IBCSG 25-02): Tamoxifen and Exemestane Trial. http://www.ibcsg.org. Accessed October 2007.
72. Goldhirsch A, Wood WC, Gelber RD, et al.: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007, 18:1133-1144.
73. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (Version 2.2007). 2007 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed October 2007.
74. Stearns V, Davidson NE, Flockhart DA: Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J 2004, 4:143-153.